You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020158021
Dec 20203706
Jan 20214003
Feb 202168018
Mar 202198019
Apr 2021122014
May 202145021
Jun 20210025
Jul 20210018
Aug 20211020
Sep 2021008
Oct 2021110035
Nov 2021205032
Dec 202192013
Jan 20225206
Feb 20223707
Mar 20225007
Apr 20228409
May 2022322013
Jun 202273011
Jul 20225606
Aug 20225908
Sep 20228207
Oct 20228103
Nov 202266010
Dec 20226804
Jan 20234601
Feb 20235805
Mar 20233603
Apr 202328017
May 20233805
Jun 20233402
Jul 202372014
Aug 202342015
Sep 20236005
Oct 202384012
Nov 20235802
Dec 202311608
Jan 20245001
Feb 20245204
Mar 20244203
Apr 20245207
May 20244601
Jun 20244203
Jul 20244000
Aug 20241802
Sep 20244403
Oct 20244005
Nov 20242203
Dec 20243205
Jan 20252809
Feb 2025401
Mar 2025004
Apr 2025003
May 2025004
Jun 2025003
Total31900494